- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | SL Science presents glioblastoma treatment data at WCP 2026 | 3 | Investing.com | ||
| 17.07. | SL Science präsentiert Daten zur Glioblastom-Behandlung auf Weltkongress | 1 | Investing.com Deutsch | ||
| 17.07. | SL Science Holding Limited: SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology | 1 | GlobeNewswire (USA) | ||
| 10.07. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.07. | SL Science seeks orphan drug status for brain cancer therapy | 4 | Investing.com | ||
| 10.07. | Hirntumortherapie: SL Science beantragt Orphan-Drug-Status | 3 | Investing.com Deutsch | ||
| SL SCIENCE Aktie jetzt für 0€ handeln | |||||
| 10.07. | SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma | 565 | GlobeNewswire (Europe) | Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative... ► Artikel lesen | |
| 18.06. | SL Science Holding Limited Reports Full Year 2025 Financial Results | 510 | GlobeNewswire (Europe) | Taipei, TAIWAN, June 18, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited ("SL Science" or the "Company") (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative... ► Artikel lesen | |
| 18.06. | SL Science Holding Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 15.06. | SL Science Holding Ltd - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 12.06. | SL Science Holding Limited: SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market | 1.014 | GlobeNewswire (Europe) | Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol "SLBT"Transaction provides strategic capital to advance proprietary Gamma... ► Artikel lesen | |
| 11.06. | SL Science Holding Ltd - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 06.02. | Horizon Space Acquisition II nominiert vor Fusion mit SL Bio unabhängige Verwaltungsratsmitglieder | 1 | Investing.com Deutsch | ||
| 14.01. | SL Science Holding Limited: SL BIO Ltd. and Horizon Space Acquisition II Corp. Announce Registration Statement Effectiveness and Extraordinary General Meeting Date to Approve Business Combination | 303 | GlobeNewswire (Europe) | TAIPEI, Taiwan & NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. ("SL Bio" or the "Company"), a biomedical company specializing in developing innovative cellular and gene therapies, and Horizon... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,345 | +0,03 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| ERASCA | 19,430 | +1,67 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| VERADERMICS | 109,99 | 0,00 % | Weekly Buzz: Novartis, Merck & Co. Win FDA Nod; Eli Lilly Snaps Up AtaiBeckley; Veradermics Shines On Hair Loss Data | BASEL (dpa-AFX) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,710 | +2,39 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,430 | +4,05 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| MAPLIGHT THERAPEUTICS | 13,480 | -63,13 % | MapLight Therapeutics, Inc.: MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia | The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo... ► Artikel lesen | |
| EVOTEC | 3,462 | +0,23 % | Millionenverluste bei Eutelsat! Warnung sowie Panik bei Evotec! Rettet Zefiro Methane Ihr Depot? | Die geopolitische Lage spitzt sich aktuell dramatisch zu. Die jüngsten Nachrichten aus dem Nahen Osten überschlagen sich. Ein massiver militärischer Schlagabtausch zwischen den USA und dem Iran droht... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 321,49 | -1,17 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies |
FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,32 | +0,03 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| SUMMIT THERAPEUTICS | 14,040 | +2,78 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| KINIKSA PHARMACEUTICALS | 64,48 | +2,61 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 | ||
| KYMERA THERAPEUTICS | 112,16 | +1,44 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,530 | +1,71 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,210 | +2,18 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| ENLIVEN THERAPEUTICS | 55,52 | +4,85 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen |
Das Unternehmen SL SCIENCE HOLDING LIMITED kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,830 Euro und damit -9,29 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SL SCIENCE HOLDING LIMITED finden Sie auf Wallstreet Online.